Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Average Recommendation of “Hold” by Brokerages

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) have earned a consensus rating of “Hold” from the ten analysts that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating and three have assigned a buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $9.33.

Several research firms recently weighed in on FULC. Leerink Partners restated a “market perform” rating and issued a $4.00 price objective on shares of Fulcrum Therapeutics in a report on Thursday, September 12th. Stifel Nicolaus lowered shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and reduced their price target for the company from $22.00 to $3.00 in a report on Thursday, September 12th. Cantor Fitzgerald downgraded shares of Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Thursday, September 12th. HC Wainwright reissued a “neutral” rating and issued a $4.00 price objective on shares of Fulcrum Therapeutics in a research note on Thursday, November 14th. Finally, Bank of America cut Fulcrum Therapeutics from a “neutral” rating to an “underperform” rating and dropped their target price for the company from $10.00 to $2.00 in a research report on Thursday, September 12th.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in FULC. National Bank of Canada FI lifted its holdings in shares of Fulcrum Therapeutics by 869.6% in the 2nd quarter. National Bank of Canada FI now owns 4,460 shares of the company’s stock worth $28,000 after acquiring an additional 4,000 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Fulcrum Therapeutics by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company’s stock worth $43,000 after purchasing an additional 4,701 shares in the last quarter. SG Americas Securities LLC boosted its position in shares of Fulcrum Therapeutics by 26.5% during the third quarter. SG Americas Securities LLC now owns 33,019 shares of the company’s stock worth $118,000 after buying an additional 6,926 shares during the period. Profund Advisors LLC acquired a new stake in shares of Fulcrum Therapeutics in the second quarter valued at $68,000. Finally, American Century Companies Inc. raised its holdings in shares of Fulcrum Therapeutics by 13.2% in the 2nd quarter. American Century Companies Inc. now owns 104,371 shares of the company’s stock valued at $647,000 after buying an additional 12,167 shares during the period. 89.83% of the stock is currently owned by institutional investors and hedge funds.

Fulcrum Therapeutics Trading Down 8.4 %

NASDAQ:FULC opened at $4.48 on Thursday. The company has a market cap of $241.65 million, a price-to-earnings ratio of -14.45 and a beta of 2.06. Fulcrum Therapeutics has a twelve month low of $2.86 and a twelve month high of $13.70. The stock has a fifty day simple moving average of $3.94 and a 200-day simple moving average of $5.55.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.